MiMedx Group (MDXG) Offers FY18 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
MiMedx Forecasts 2018 Revenue To Be In The Range Of $383 Million To $387 Million
December 13, 2017 7:00 AM ESTMARIETTA, Ga., Dec. 13, 2017 /PRNewswire/ --Â MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today its guidance for full year 2018.
Full Year 2018 Guidance Highlights:The Company's full year 2018 expectations include:
Revenue estimated between $383 to $387 million Gross profit margins expected to be in the range of 89% to 90% Operating Income expected to be in... More